Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage.
Christiansen SH, Zhang X, Juul-Madsen K, Hvam ML, Vad BS, Behrens MA, Thygesen IL, Jalilian B, Pedersen JS, Howard KA, Otzen DE, Vorup-Jensen T. Christiansen SH, et al. Among authors: howard ka. Biochim Biophys Acta Biomembr. 2017 Mar;1859(3):425-437. doi: 10.1016/j.bbamem.2017.01.001. Epub 2017 Jan 5. Biochim Biophys Acta Biomembr. 2017. PMID: 28064019 Free article.
Size-Selective Phagocytic Clearance of Fibrillar α-Synuclein through Conformational Activation of Complement Receptor 4.
Juul-Madsen K, Qvist P, Bendtsen KL, Langkilde AE, Vestergaard B, Howard KA, Dehesa-Etxebeste M, Paludan SR, Andersen GR, Jensen PH, Otzen DE, Romero-Ramos M, Vorup-Jensen T. Juul-Madsen K, et al. Among authors: howard ka. J Immunol. 2020 Mar 1;204(5):1345-1361. doi: 10.4049/jimmunol.1900494. Epub 2020 Jan 22. J Immunol. 2020. PMID: 31969389
Bioengineered solutions to improve cancer immunotherapies.
Mandrup OA, Howard KA. Mandrup OA, et al. Among authors: howard ka. Ther Deliv. 2021 May;12(5):339-341. doi: 10.4155/tde-2021-0019. Epub 2021 Mar 17. Ther Deliv. 2021. PMID: 33726505 No abstract available.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup OA, Erce-Llamazares A, Lázaro-Gorines R, Nehme-Álvarez D, Domínguez-Alonso C, Harwood SL, Alfonso C, Blanco B, Rubio-Pérez L, Jiménez-Reinoso A, Díez-Alonso L, Blanco FJ, Sanz L, Howard KA, Álvarez-Vallina L. Hangiu O, et al. Among authors: howard ka. iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. eCollection 2022 Sep 16. iScience. 2022. PMID: 36072551 Free PMC article.
Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design.
Glud EN, Rasmussen M, Zhang Y, Mandrup OA, Salachan PV, Borre M, Sørensen KD, Howard KA. Glud EN, et al. Among authors: howard ka. Br J Cancer. 2022 Dec;127(12):2186-2197. doi: 10.1038/s41416-022-01994-1. Epub 2022 Oct 15. Br J Cancer. 2022. PMID: 36243890 Free PMC article.
162 results